U.S. Markets open in 5 hrs 55 mins

Palatin Technologies, Inc. (PTN)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.4585-0.0014 (-0.30%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4599
Open0.4562
Bid0.4585 x 800
Ask0.4563 x 3100
Day's Range0.4471 - 0.4630
52 Week Range0.3800 - 1.3000
Volume487,950
Avg. Volume1,240,682
Market Cap105.478M
Beta (5Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-0.1190
Earnings DateMay 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Palatin to Present Peptides Platform at the TIDES USA Conference

    Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced a featured speaker presentation and two poster presentations at the upcoming TIDES USA hybrid conference in Boston, Massachusetts on September 20-23, 2021.

  • PR Newswire

    Palatin to Participate in H.C. Wainwright 23rd Annual Global Investment Virtual Conference

    Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that Carl Spana, Ph.D., President and Chief Executive Officer, will participate in the H.C. Wainwright 23rd Annual Global Investment Virtual Conference on September 13-15, 2021.

  • PR Newswire

    Palatin Announces Presentation at the Eyecelerator@ASCRS Conference

    Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that Carl Spana, PhD, President and CEO of Palatin, presented today at the Eyecelerator@ASCRS Conference in Las Vegas, NV. The presentation is one of several Company Showcases in the general session titled: "Dry Eye: The Need for Innovation." The topics of the present